Taking a mix of good bacteria for six weeks might help lower bad cholesterol and inflammation while improving good cholesterol and blood sugar control, especially if also taking fish oil.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Provide a pooled estimate of the effect of VSL#3 on cardiometabolic markers across all available trials.
A systematic review and meta-analysis of ≥5 RCTs using VSL#3 in adults with overweight or metabolic syndrome, reporting changes in lipid profile, hsCRP, and HOMA-IR, with minimum 6-week duration and 100+ total participants.
Establish causal effects of VSL#3 alone and with omega-3 on cardiometabolic outcomes.
A double-blind, placebo-controlled 2×2 factorial RCT with 300+ overweight adults randomized to VSL#3, omega-3, both, or placebo for 6 weeks, measuring lipid panel, hsCRP, HOMA-IR, and gut microbiota as primary outcomes.
Assess real-world associations between probiotic use and cardiometabolic health trends.
A 1-year prospective cohort of 2,000 adults tracking probiotic and omega-3 supplement use and annual changes in cholesterol, inflammation, and insulin resistance, adjusting for diet and lifestyle.
Reveal current associations between probiotic use and metabolic health status.
A cross-sectional analysis of 3,000 adults from a national health survey, comparing lipid and inflammatory markers between probiotic users and non-users.
Synthesize current understanding and mechanistic plausibility.
An expert review discussing the biological mechanisms by which VSL#3 may influence metabolism, citing animal and human studies.